{"id":"antifungal-comparator","safety":{"commonSideEffects":[{"rate":"10%","effect":"Hepatotoxicity"},{"rate":"5%","effect":"Rash"},{"rate":"3%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the inhibition of enzymes involved in the biosynthesis of the fungal cell wall, ultimately leading to the death of the fungal cells.","oneSentence":"Antifungal mechanism involves inhibiting fungal cell wall synthesis","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:47.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fungal infections"}]},"trialDetails":[{"nctId":"NCT06925321","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2025-08-26","conditions":"Invasive Mold Infections","enrollment":219},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT06789588","phase":"PHASE3","title":"Protocol for Improvement of Therapy With Warfarin","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pernambuco","startDate":"2024-10-21","conditions":"Atrial Fibrillation (AF)","enrollment":700},{"nctId":"NCT05279846","phase":"PHASE3","title":"A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Moberg Pharma AB","startDate":"2022-05-09","conditions":"Onychomycosis","enrollment":350},{"nctId":"NCT03897257","phase":"PHASE2","title":"A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2019-03-15","conditions":"Tinea Pedis","enrollment":240},{"nctId":"NCT03253094","phase":"PHASE2","title":"Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2017-08-01","conditions":"Candida Vulvovaginitis","enrollment":186},{"nctId":"NCT00934934","phase":"PHASE2","title":"Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment","status":"TERMINATED","sponsor":"Daren K. Heyland","startDate":"2010-04","conditions":"Ventilator Associated Pneumonia, Respiratory Tract Infection","enrollment":61},{"nctId":"NCT00076869","phase":"PHASE2","title":"MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-01","conditions":"Aspergillosis","enrollment":55},{"nctId":"NCT01344681","phase":"PHASE2","title":"Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-06","conditions":"Febrile Neutropenia, Hematological Diseases","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":164,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Antifungal Comparator","genericName":"Antifungal Comparator","companyName":"Elion Therapeutics, Inc.","companyId":"elion-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EL219, a small molecule antifungal, is being studied in a Phase 2 clinical trial for the treatment of Invasive Mould Infection, Onychomycosis, Candida Vulvovaginitis, Atrial Fibrillation, and Ventilator Associated Pneumonia. The trial compares EL219 to IV antifungal medications, specifically liposomal amphotericin B or voriconazole.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}